Kodiak Sciences (MEX:KOD) EBITDA Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KOD Kodiak Sciences Inc MEX:KOD
27 GF Score
Price MXN749.00
! 4 Warning Signs
View Full Analysis

What is Kodiak Sciences EBITDA Margin %?

Kodiak Sciences MEX:KOD 27 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, Kodiak Sciences ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kodiak Sciences's EBITDA for the three months ended in Mar. 2026 was MXN-963.61 Mil. Kodiak Sciences's Revenue for the three months ended in Mar. 2026 was MXN0.00 Mil. Therefore, Kodiak Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Kodiak Sciences  (MEX:KOD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Kodiak Sciences EBITDA Margin % Related Terms

Kodiak Sciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences EBITDA Margin % Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kodiak Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:KOD vs ABCL, AGIO, IMNM: EBITDA Margin % Comparison

For the Biotechnology subindustry, Kodiak Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kodiak Sciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's EBITDA Margin % falls into.


MEX:KOD
27GF Score
Kodiak Sciences Inc MEX:KOD
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kodiak Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3666.807/0
= %

Kodiak Sciences's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-963.613/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Kodiak Sciences (MEX:KOD) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #999999 out of 939 companies in the Biotechnology industry.
Is Kodiak Sciences' EBITDA Margin % too high?
Kodiak Sciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Kodiak Sciences ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' EBITDA Margin % compare to ABCL and AGIO?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #999999 out of 939 companies for EBITDA Margin %. This places Kodiak Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges KOD:USAK27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score

Get the complete analysis for MEX:KOD

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN749.00
Price